This page shows what was measured, who it was measured in, and what that does not settle.
What Lurasidone does in the body
Lurasidone blocks the dopamine receptor that antipsychotics have blocked since the 1950s, and blocks two serotonin receptors alongside it.
What makes it different is what it deliberately does not touch: it barely binds the histamine and acetylcholine receptors, and those are the receptors responsible for most of the weight gain, sedation, dry mouth and constipation that the older drugs in this class cause. It has to be swallowed with a real meal of at least 350 calories, because on an empty stomach the body absorbs roughly half as much.
Why people take it. Schizophrenia, and the depressed phase of bipolar disorder
What happened in people
A standardised mean difference of 0.33 against placebo for overall symptom change in acute schizophrenia, equal-lowest of fifteen ranked antipsychotics
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
The limit that matters most
One of only two drugs with a monotherapy indication for bipolar depression, alongside quetiapine
Where it acts
Mesolimbic and mesocortical dopamine synapses, with 5-HT7 and 5-HT1A binding in cortical and hippocampal circuits proposed as the basis of the mood effect
Kind of result
Symptoms and quality of life
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 22IC88528T · read 2026-08-29
Its recorded molecular formula is C28H36N4O2S·HCl, weighing 529.14.
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The recorded use, written for a reader without medical training. Not signed off.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 118 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Absolute difference
An absolute difference is how many more people in a hundred were affected.
A picture of it, and where the picture fails
It is like counting heads in two rooms of a hundred.
Where that stops being true. Heads are easy to count. Study results carry a margin of error too.
What people get wrong. It is confused with a percentage change, which can look far larger.
The arithmetic difference in event rates between arms.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Mean change from baseline in Montgomery-Asberg Depression Rating Scale total score at week 6 in bipolar I depression
Least-squares mean change -15.4 on both lurasidone dose ranges against -10.7 on placebo; mean difference -4.6 for each arm, p<0.001 by mixed-model analysis
Repeated elsewhere
Partially Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The higher dose range produced exactly the same MADRS change as the lower one, so the trial provides no dose-response gradient for the effect it established.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
Mean change from baseline in MADRS total score at week 6 in bipolar I depression, added to lithium or divalproex
Least-squares mean change -17.1 against -13.5 on placebo; mean difference -3.6, p=0.005
Repeated elsewhere
Failed to Replicate
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. This is the positive half of a two-trial adjunctive programme. The second and larger trial of the same question, NCT01284517, did not separate from placebo.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
Mean change from baseline in MADRS total score at week 6 in bipolar I depression in patients not responding to lithium or divalproex alone
Least-squares mean change -11.8 against -10.4 on placebo; mean difference -1.5, p=0.176
Repeated elsewhere
Failed to Replicate
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Larger than the positive adjunctive trial it was meant to confirm, and completed in August 2012 after that trial had reported. The adjunctive indication remains on the United States label.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
Time to recurrence of a mood event during the double-blind phase, lurasidone adjunctive to lithium or divalproex
Hazard ratio 0.71 (95% CI 0.49 to 1.04), p<0.078 by Cox proportional hazards; median time to recurrence not reached on lurasidone against 207 days on placebo
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. The secondary endpoint of time to all-cause discontinuation did separate, hazard ratio 0.72 (95% CI 0.54 to 0.98), p<0.034. There is no bipolar maintenance indication on the United States label.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
Time to first relapse event during the double-blind phase in schizophrenia
Log-rank p=0.039, ratio 0.66 (95% CI 0.45 to 0.98); median time to relapse not reached on lurasidone against 192 days on placebo
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Time to all-cause discontinuation, the secondary endpoint that captures tolerability as well as relapse, did not reach significance: 0.75 (95% CI 0.54 to 1.03), p=0.070, with median 148 days on lurasidone against 115 on placebo.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
Mean overall change in symptoms against placebo in acute schizophrenia, with all-cause discontinuation, weight gain, extrapyramidal effects, prolactin, QTc and sedation as secondary outcomes
✓ The study showed what it set out to show
Who was studied
Leucht 15-drug multiple-treatments meta-analysis
How many people
43049
Study design
Bayesian network meta-analysis of 212 blinded randomised trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Lurasidone standardised mean difference 0.33 (95% CrI 0.21 to 0.45), fourteenth of fifteen; QTc effect 0.10, the most favourable of the fifteen
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The drug with the best cardiac signal in the analysis also had the equal-weakest effect on symptoms. Both findings come from the same pooled dataset.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet taken once daily with food of at least 350 calories
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
NCT01284517 — Lurasidone adjunctive to lithium or divalproex in bipolar I depression after non-response, posted results showing p=0.176 on the primary endpoi… · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Lurasidone
What a person takes: Oral tablet taken once daily with food of at least 350 calories.
The measurement behind this step
There is no injectable, no long-acting form and no orally disintegrating form. The food requirement is a genuine constraint on the drug rather than a labelling formality: absorption is estimated at 9 to 19% of an administered dose, and taking the tablet fasting roughly halves total exposure and cuts peak concentration to about a third of the fed value. Clearance is almost entirely through CYP3A4, and the label contraindicates strong inhibitors and strong inducers of that enzyme rather than dose-adjusting around them.
Getting in
A once-daily tablet that only works if it is swallowed with a meal
Lurasidone is taken once a day with food of at least 350 calories. On an empty stomach the body absorbs roughly half as much, so the meal is part of the dose, not advice about comfort.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Only an estimated 9 to 19% of an administered dose is absorbed. In the food-effect study mean Cmax was about three times and AUC about twice the fasting values, and exposure did not increase further from a 350 to a 1,000 calorie meal or vary with fat content. Peak concentration is reached in 1 to 3 hours and steady state within about seven days.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
Reaching the cell
It crosses into the brain and is cleared almost entirely by one liver enzyme
The drug reaches the brain and is broken down mainly by a single liver enzyme, which is why a handful of common medicines and grapefruit juice change how much of it is in the body.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Activity is primarily due to the parent compound rather than a metabolite. Clearance is predominantly via CYP3A4, and the label contraindicates strong CYP3A4 inhibitors and strong inducers outright rather than adjusting around them. Plasma protein binding is about 99% and the apparent volume of distribution around 6,173 L.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
What it acts on
It occupies dopamine D2 and serotonin 5-HT2A and 5-HT7 tightly
It sits on the dopamine receptor that every antipsychotic since the 1950s has targeted, and on two serotonin receptors alongside it, switching all three off.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Antagonism with Ki of 1 nM at D2, 0.5 nM at 5-HT2A and 0.5 nM at 5-HT7. The 5-HT7 affinity is unusually high for this class and is the receptor most often invoked to explain the antidepressant signal in bipolar depression, though that link is a hypothesis rather than a demonstrated mechanism. Partial agonism at 5-HT1A with Ki 6.4 nM is proposed to contribute in the same direction.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
The change it makes
It leaves the histamine and acetylcholine receptors alone
The receptors that make older drugs in this class sedating, appetite-driving and dry-mouthed are the ones lurasidone was designed to miss. That absence is the point of the molecule.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The label records IC50 above 1,000 nM at both histamine H1 and muscarinic M1, three orders of magnitude weaker than its D2 affinity. H1 blockade is the principal driver of sedation and appetite stimulation in this class, and M1 blockade of dry mouth, constipation, urinary retention and cognitive blunting. The bulky bicyclic norbornane imide at one end of the molecule is the structural feature that keeps it off those sites.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
What that does for a person
Symptoms fall modestly, weight and the electrocardiogram stay put, akathisia appears
The effect on symptoms is at the low end of what antipsychotics achieve. What stays normal is weight, blood sugar, cholesterol and the heart tracing. The characteristic complaint is restlessness and an urge to keep moving.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Standardised mean difference against placebo of 0.33 (95% CrI 0.21 to 0.45) for overall symptom change, equal-lowest of fifteen. QTc effect at the favourable extreme of the same fifteen-drug range (SMD 0.10). Akathisia, somnolence, nausea and parkinsonism are the most frequent adverse reactions in the label's pooled short-term data, and akathisia is dose-related.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults and adolescents with schizophrenia, and adults and children aged 10 and over with bipolar depression. It is chosen most often for people whose weight, blood sugar or cholesterol rules out olanzapine or quetiapine.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of lurasidone hydrochloride has not been established in pediatric patients less than 10 years of age with bipolar depression.”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
On older people, the label states: “Clinical studies with lurasidone hydrochloride did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients.”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
On people who are pregnant, the label states: “Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride during pregnancy.”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Lactation studies have not been conducted to assess the presence of lurasidone in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
On people with reduced liver function, the label states: “Reduce the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score ≥7).”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
On people with reduced kidney function, the label states: “Reduce the maximum recommended dosage in patients with moderate or severe renal impairment (CL cr <50 mL/minute).”
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
Where the result stopped carrying
NCT01284517, the 356-patient replication of the adjunctive bipolar depression indication, returned a 1.5-point MADRS difference at p=0.176
NCT01358357, the 965-patient bipolar maintenance trial, missed its primary endpoint at p<0.078
In Study 4 of the schizophrenia registration programme, 489 patients on three fixed doses, only the middle dose beat placebo
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral tablet taken once daily with food of at least 350 calories
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S6.
No source is stored against this line.
What is in the pack
There is no injectable, no long-acting form and no orally disintegrating form.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold. The rest of the recorded wording: The food requirement is a genuine constraint on the drug rather than a labelling formality: absorption is estimated at 9 to 19% of an administered dose, and taking the tablet fasting roughly halves total exposure and cuts peak concentration to about a third of the fed value. Clearance is almost entirely through CYP3A4, and the label contraindicates strong inhibitors and strong inducers of that enzyme rather than dose-adjusting around them.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
The United States label carries boxed warnings for increased mortality in elderly patients with dementia-related psychosis and for suicidal thoughts and behaviours in children, adolescents and young adults. The most frequent adverse reactions in the pooled short-term data are somnolence, akathisia, extrapyramidal symptoms and nausea, with akathisia dose-related. Weight gain, lipid and glucose disturbance are at the favourable end of the class range, as is the QTc effect. Neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension, leukopenia, neutropenia and agranulocytosis, seizures and hyperprolactinaemia are all in the label.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results (NCT00868699) · a recorded source, not a stored snapshot
NCT00868452 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Add-on), posted results (NCT00868452) · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral tablet taken once daily with food of at least 350 calories
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
A recorded note compares this form with the others that are sold. It is kept below, word for word.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
The recorded note, unchanged: The food requirement is a genuine constraint on the drug rather than a labelling formality: absorption is estimated at 9 to 19% of an administered dose, and taking the tablet fasting roughly halves total exposure and cuts peak concentration to about a third of the fed value. Clearance is almost entirely through CYP3A4, and the label contraindicates strong inhibitors and strong inducers of that enzyme rather than dose-adjusting around them.
No source is stored against this line.
What is recorded as being sold
176 products list this as an active ingredient in the United States drug directory. 176 of them contain it and nothing else.
FDA National Drug Code directory · 72189-598 · read 2026-08-29
They are sold as powder, tablet, tablet, coated and tablet, film coated, taken oral.
FDA National Drug Code directory · 72189-598 · read 2026-08-29
The regulator's established pharmacologic class for it is atypical antipsychotic [epc].
FDA National Drug Code directory · 72189-598 · read 2026-08-29
41 published labels name it as an active ingredient. 41 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-29
Lurasidone Hydrochloride is oral at 3 DOSAGE FORMS AND STRENGTHS Lurasidone hydrochloride tablets are available in the following shape and color (Table 1) with debossing., recorded as fda label in effect 2023-01-25 in the United States.
US prescribing information · 27f70e15-ee22-47ae-ba87-20e2b4a1a4d6 · read 2026-08-30
Recorded price in US: 0.13756–0.48239 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 86 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Lurasidone studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That the adjunctive bipolar depression indication is supported by replicated evidence — the second and larger trial of that question returned p=0.176
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a favourable weight, lipid, glucose and QTc profile means fewer cardiovascular events or longer life — no trial of this drug has measured those endpoints
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That lurasidone prevents recurrence in bipolar disorder — the maintenance trial's primary endpoint had a 95% confidence interval crossing 1.00 and there is no such indication
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That taking the tablet at a convenient time is equivalent to taking it as tested — every efficacy figure here comes from fed dosing
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Lurasidone are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
The most favourable QT signal of the fifteen antipsychotics ranked together
In plain words
Across 212 trials and 43,049 patients, lurasidone sat at the good end of the range for effects on the heart's electrical recovery time. It is the one property on which it beat every other drug in the comparison.
What was measured
Standardised mean difference against placebo for QTc prolongation, and maximum mean baseline-adjusted QTcI change in a dedicated thorough QT study
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
In the Leucht multiple-treatments meta-analysis, standardised mean differences against placebo for QTc prolongation ran from 0.10 for the best drug, lurasidone, to -0.90 for the worst, sertindole. The label's dedicated thorough QT study in 43 patients with schizophrenia or schizoaffective disorder found a maximum mean increase in baseline-adjusted QTcI of 7.5 ms (upper one-sided 95% CI 11.7) at 120 mg daily and 4.6 ms (upper 95% CI 9.5) at 600 mg daily, with no apparent dose-response relationship, and no post-baseline QT above 500 ms in either arm of the short-term placebo-controlled studies.
Written into the record, not signed off as a reviewed claim
Bipolar depression on its own: 4.6 MADRS points better than placebo
In plain words
In 505 patients with the depressed phase of bipolar disorder, six weeks of lurasidone alone improved the depression score by about fifteen points against about eleven on placebo. Both dose ranges tested gave the same result.
What was measured
Least-squares mean change from baseline in MADRS total score at week 6 against placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
NCT00868699 randomised 505 patients with bipolar I depression to a lower or higher lurasidone dose range or placebo for six weeks. Least-squares mean change from baseline in MADRS total score was -15.4 in both lurasidone arms against -10.7 on placebo, a mean difference of -4.6 for each arm, p<0.001 by mixed-model analysis. The absence of a dose-response gradient between the two ranges is itself worth stating: the higher range bought nothing on the primary endpoint.
Source
NCT00868699 — Lurasidone, A 6-week Study of Patients With Bipolar I Depression (Monotherapy), posted results, Sumitomo Pharma America
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
The add-on bipolar indication rests on one positive trial and one negative one of the same design
In plain words
Two six-week trials tested lurasidone added to lithium or valproate in bipolar depression. The first, in 348 patients, worked. The second, in 356 patients, did not. The label carries the indication.
What was measured
Least-squares mean difference in MADRS change at week 6 against placebo: -3.6 (p=0.005) in the first adjunctive trial and -1.5 (p=0.176) in the second
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
NCT00868452 randomised 348 patients already taking lithium or divalproex and reported a least-squares mean MADRS change of -17.1 on lurasidone against -13.5 on placebo, a difference of -3.6, p=0.005. NCT01284517, a randomised, six-week, double-blind, placebo-controlled, flexible-dose study of the same adjunctive question in patients who had not responded to lithium or divalproex alone, randomised 356 patients and reported -11.8 against -10.4, a difference of -1.5, p=0.176. The second study is larger than the first and ran from November 2010 to August 2012, after the first had read out. Both results are posted on ClinicalTrials.gov. A reader told only about the positive trial has been shown half of a two-trial replication attempt in which the replication failed.
Source
NCT00868452 and NCT01284517, posted results, Sumitomo Pharma America
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
The bipolar maintenance trial missed, and there is no maintenance indication
In plain words
A 965-patient trial asked whether staying on lurasidone alongside a mood stabiliser delays the next episode of mania or depression. It did not reach statistical significance, and the drug has never been approved for that use.
What was measured
Hazard ratio for time to recurrence of a mood event: 0.71 (95% CI 0.49 to 1.04), p<0.078
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
NCT01358357, a phase 3 double-blind maintenance study of lurasidone adjunctive to lithium or divalproex, enrolled 965 participants and ran from June 2011 to April 2015. The primary endpoint, time to recurrence of a mood event during the double-blind phase, gave a hazard ratio of 0.71 (95% CI 0.49 to 1.04) with p<0.078 by Cox proportional hazards, against a design powered at 90% to detect a 15% difference in recurrence rates with 120 events. Median time to recurrence was not reached on lurasidone against 207 days on placebo. The secondary endpoint of time to all-cause discontinuation did separate, hazard ratio 0.72 (95% CI 0.54 to 0.98), p<0.034. A confidence interval crossing 1.00 on the primary endpoint and a significant secondary is the classic shape of a trial that will be described afterwards as encouraging. The United States label carries no maintenance indication for bipolar disorder.
Source
NCT01358357 — Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex, posted results, Sumitomo Pharma America
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
Equal-lowest effect on symptoms of the fifteen drugs compared
In plain words
On the pooled measure of how much antipsychotics reduce symptoms in acute schizophrenia, lurasidone came fourteenth of fifteen, tied with iloperidone and below chlorpromazine, a drug from 1957.
What was measured
Standardised mean difference against placebo for overall symptom change
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Standardised mean difference against placebo for overall symptom change was 0.33 (95% CrI 0.21 to 0.45) for lurasidone, placing it fourteenth of fifteen alongside iloperidone at 0.33 and below chlorpromazine 0.38, asenapine 0.38, ziprasidone 0.39, sertindole 0.39, aripiprazole 0.43, quetiapine 0.44, haloperidol 0.45, zotepine 0.49, paliperidone 0.50, risperidone 0.56, olanzapine 0.59, amisulpride 0.66 and clozapine 0.88. The authors concluded that differences in efficacy between antipsychotics are small but robust. Lurasidone's advantages are real and they are in the tolerability domains, not this one, and a page that quotes the metabolic profile without this figure has described a trade-off as a free lunch.
Written into the record, not signed off as a reviewed claim
In the registration programme, the middle dose worked and the two around it did not
In plain words
One of the five schizophrenia trials that established this drug tested three fixed doses in 489 patients. Only the middle one beat placebo. The lower and the higher dose both failed.
What was measured
Change in PANSS total score and CGI-S at week 6 against placebo, by fixed dose arm
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Section 14.1 of the United States prescribing information describes Study 4 as a six-week placebo-controlled trial with 489 patients on three fixed doses, and records that only the 80 mg per day arm was superior to placebo on PANSS total score and CGI-S at endpoint. The 40 mg and 120 mg arms were not, even though the 40 mg and 120 mg arms of Study 3 both were. A monotonic dose-response is the pattern a pharmacological effect predicts, and this programme does not show one. Two of the five trials also carried an active control, olanzapine in one and extended-release quetiapine in the other, specifically to establish assay sensitivity, which is the standard admission that a negative arm in this field is as likely to be a failed trial as an ineffective drug.
Source
United States prescribing information for lurasidone hydrochloride, section 14.1, via the openFDA drug label endpoint
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
A better metabolic profile is not a measured cardiovascular outcome
In plain words
Lurasidone causes less weight gain and less disturbance of blood sugar and cholesterol than olanzapine. Nobody has shown that people taking it have fewer heart attacks or live longer.
What was measured
That the favourable weight, lipid, glucose and QTc profile translates into fewer cardiovascular events or longer life — no trial of this drug has measured that endpoint
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
What was measured in the registration and comparative programmes are surrogate endpoints: kilograms, fasting glucose, lipid fractions and QTc milliseconds. The clinical claim that gets built on them is a reduction in cardiovascular events and in the mortality gap that people with schizophrenia carry, which runs to roughly fifteen to twenty years of life expectancy. No randomised trial of lurasidone has measured myocardial infarction, stroke or death as a primary endpoint, and the two long trials that exist measured time to relapse and time to recurrence over months, not cardiovascular events over years. The surrogate improvements are genuine and well measured. The outcome inference from them is untested.
This order is fixed in code and does not count clicks or time on the page.
What is not here
7 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A dopamine D2 and serotonin 5-HT2A antagonist built to avoid the histamine and muscarinic receptors that drive weight gain and sedation, which produced the most favourable QT signal of the fifteen antipsychotics ever ranked together and the equal-lowest effect on symptoms (standardised mean difference 0.33), works in bipolar depression on its own (MADRS 4.6 points better than placebo in 505 patients), and carries an add-on bipolar indication supported by one positive trial and one negative one.
Recorded evidence blocks (9)
Q2
On the Lurasidone label: indicated for what?
"Lurasidone hydrochloride is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see…": indications and usage on Lurasidone's label. DailyMed label · bceb350e-4b88-4de1-9629-9629365a27a7 · 2026-07-28
Q3
76 registered trials of Lurasidone — at which phases?
"On hold due to competing departmental studies"; 5 of 76 registered studies
Show the evidence
Trial
NCT01932541
withdrawn; "On hold due to competing departmental studies"
NCT02893371
terminated; "Per PI, this study is not a clinical trial and was inadvertently entered in the system"
NCT04383691
terminated; "Company's business decision"
NCT05213143
terminated; "Company's business decision"
NCT06328140
withdrawn; "we were unable to recruit participants according to the original protocol specifications. The sponsor would not allow for a modification so the study was stopped."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Lurasidone used Lurasidone 20 mg — over how long?
studies of Lurasidone used the recorded amount. ClinicalTrials.gov · 2026-09-01
19 recorded entries; human; tablet; also "Lurasidone 20 mg", "Lurasidone 40 mg", "Lurasidone 80mg"
Show the evidence
human
NCT00044005
Lurasidone 20 mg
NCT00044005
Lurasidone 40 mg
NCT00044005
Lurasidone 80mg
NCT00044044
Lurasidone 40mg
NCT00044044
Lurasidone 80 mg
NCT00088621
tablet; Lurasidone 80mg tablet
13 more recorded rows
humanNCT00615433
Lurasidone 40 mg tablets
humanNCT01423240
Lurasidone 60 mg
humanNCT01614899
SM-13496 40mg
humanNCT01614899
SM-13496 80mg
humanNCT01821378
Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
humanNCT01911442
Lurasidone 20 mg daily
humanNCT01914393
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
humanNCT01979679
Lurasidone 120 mg
humanNCT01979679
Lurasidone 160 mg
humanNCT02174510
20mg lurasidone
humanNCT02174510
40mg lurasidone
humanNCT02174510
80mg lurasidone
humanNCT03465787
Lurasidone HCL 160 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which 20 trials of Lurasidone posted no result?
Posted no result
20 of 20 completed trials
Registrations
NCT00549666, NCT01082146, NCT01082276, NCT01082250, NCT01074073 and NCT01082289, and 14 more
Completion dates
oldest 2007-12; newest 2024-03-30
Show the evidence
Trial
NCT00549666
2007-12
NCT01082146
2008-08
NCT01082276
2008-08
NCT01082250
2008-09
NCT01074073
2008-10
NCT01082289
2008-10
14 further recorded trials
NCT01082263
2008-11
NCT01074632
2009-09
NCT02147379
2017-01-12
NCT01498770
2017-12-21
NCT03304457
2018-03-25
NCT03393026
2019-09-17
NCT01431326
2019-11
NCT03402152
2021-06-01
NCT03465787
2022-10-26
NCT04312503
2022-10-31
NCT05011669
2023-06-16
NCT04432688
2023-06-18
NCT06527885
2023-09-12
NCT03395392
2024-03-30
Q7
At the median, Lurasidone's trials enrolled 136.5 people — anything larger?
Median enrolment
136.5
Largest enrolment
1037352
Registered trials counted
76
Q8
What do 240 spontaneous reports say about Lurasidone — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Lurasidone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 240 reaction mentions were counted: depression 33; drug interaction 33; delusion 29; weight increased 29. FAERS via Open Targets · CHEMBL1237021 · 2026-06-24
Show the evidence
depression
33
drug interaction
33
delusion
29
weight increased
29
hallucination
26
mania
20
4 more recorded rows
agitation
19
akathisia
18
sedation
17
anxiety
16
recorded 2026-06-24 · last checked 2026-09-04
Q9
Which 10 reactions does Lurasidone's label not list?
7.1 Drugs Having Clinically Important Interactions with Lurasidone Hydrochloride Table 34 Clinically Important Drug Interactions with Lurasidone Hydrochloride Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of lurasidone hydrochloride with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone [ see Clinical Pharmacology (…
drug_interactions
Intervention: Lurasidone hydrochloride should not be used concomitantly with strong CYP3A4 inhibitors [ see Contraindications ( 4 ) ].
drug_interactions
Examples: Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of lurasidone hydrochloride with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone [ see Clinical Pharmacology ( 12.3 ) ].
drug_interactions
Intervention: Lurasidone hydrochloride dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 [ see Dosage and Administration ( 2.6 ) ].
drug_interactions
Examples: Diltiazem, atazanavir, erythromycin, fluconazole, verapamil Strong CYP3A4 Inducers Clinical Impact: Concomitant use of lurasidone hydrochloride with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone [ see Clinical Pharmacology ( 12.3 ) ].
drug_interactions
Intervention: Lurasidone hydrochloride should not be used concomitantly with strong CYP3A4 inducers [ see Contraindications ( 4 ) ].
2 more recorded rows
Interaction statementdrug_interactions
John's wort, phenytoin, carbamazepine Moderate CYP3A4 Inducers Clinical Impact: Concomitant use of lurasidone hydrochloride with moderate CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride alone [ see Clinical Pharmacology ( 12.3 ) ].
Interaction statementdrug_interactions
Intervention: Lurasidone hydrochloride dose should be increased when used concomitantly with moderate inducers of CYP3A4 [ see Dosage and Administration ( 2.6 ) ].
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.